source
- Viridian's elegrobart shows strong results in chronic thyroid eye disease trial, challenging Amgen's TepezzaViridian Therapeutics announced that its injectable drug elegrobart met its primary goals in a late-stage study of patients with chronic thyroid eye disease. The trial reported response rates of 50…
- Pfizer halts final Trillium study, redirects R&D funds to cancer and obesity programsPfizer announced it is ending the last clinical trial that originated from its 2021 purchase of Trillium Therapeutics. The company said the decision will free up cash that will be redirected to a…